The ligand-activated transcription factor nuclear receptor-related 1 (Nurr1, NR4A2) 1 emerges as a highly promising target for the treatment of Parkinson's Disease (PD) and other neurodegenerative disorders . It is a member of the nerve growth factor IB-like receptor family (NR4A) and highly expressed in the CNS, particularly in dopaminergic neurons . Altered Nurr1 expression levels in patients with PD 5 , Alzheimer's Disease (AD) and multiple sclerosis (MS) as well as in well-established rodent models of neurodegenerative diseases (5XFAD and MPTP ) provide convincing evidence for a key role of Nurr1 in neurodegeneration. Moreover, heterozygous Nurr1 knockout in mice accelerated experimental autoimmune encephalomyelitis (EAE) and mice with Nurr1 knockout in dopaminergic neurons revealed a PD-like phenotype . These observations suggest great therapeutic potential of pharmacological Nurr1 modulation in neurodegenerative diseases prompting the search for Nurr1 modulating small molecules.